What is Leerink Partnrs’ Estimate for HOWL FY2024 Earnings?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Leerink Partnrs increased their FY2024 earnings per share estimates for Werewolf Therapeutics in a report released on Monday, November 11th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings of ($1.98) per share for the year, up from their prior forecast of ($2.07). The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics’ Q4 2024 earnings at ($0.80) EPS, Q1 2025 earnings at ($1.17) EPS, Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($4.15) EPS, FY2026 earnings at ($3.40) EPS, FY2027 earnings at ($2.98) EPS and FY2028 earnings at ($2.56) EPS.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL opened at $1.93 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics has a one year low of $1.66 and a one year high of $8.19. The company has a fifty day moving average price of $2.27 and a 200 day moving average price of $2.92. The stock has a market cap of $86.00 million, a P/E ratio of -1.26 and a beta of 0.41.

Institutional Investors Weigh In On Werewolf Therapeutics

Several hedge funds have recently made changes to their positions in HOWL. SG Americas Securities LLC bought a new stake in shares of Werewolf Therapeutics in the 3rd quarter worth approximately $29,000. Point72 DIFC Ltd acquired a new position in Werewolf Therapeutics in the second quarter worth about $34,000. Rhumbline Advisers bought a new position in Werewolf Therapeutics during the second quarter worth about $79,000. American Century Companies Inc. boosted its holdings in Werewolf Therapeutics by 50.7% during the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after purchasing an additional 12,656 shares in the last quarter. Finally, Murchinson Ltd. bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $152,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.